PDT Partners LLC Raises Stake in Enanta Pharmaceuticals, Inc. $ENTA

Key Points

• PDT Partners LLC increased its stake in Enanta Pharmaceuticals by 217.5% in the first quarter, now owning 106,200 shares valued at approximately $586,000.
• Several other institutional investors, including Jacobs Levy Equity Management and CWM LLC, have also significantly increased their holdings in Enanta Pharmaceuticals, indicating strong institutional interest in the company.
• Analyst ratings for Enanta Pharmaceuticals have been mostly positive, with a consensus price target of $22.25 and several analysts issuing "buy" ratings.

PDT Partners LLC raised its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 217.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 106,200 shares of the biotechnology company's stock after purchasing an additional 72,751 shares during the quarter. PDT Partners LLC owned 0.50% of Enanta Pharmaceuticals worth $586,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Trexquant Investment LP increased its holdings in Enanta Pharmaceuticals by 113.4% during the 1st quarter. Trexquant Investment LP now owns 290,059 shares of the biotechnology company's stock worth $1,601,000 after purchasing an additional 154,105 shares during the period. Ieq Capital LLC purchased a new position in Enanta Pharmaceuticals during the 1st quarter worth $232,000. MetLife Investment Management LLC purchased a new position in Enanta Pharmaceuticals during the 1st quarter worth $72,000. Stonepine Capital Management LLC increased its holdings in Enanta Pharmaceuticals by 78.0% during the 1st quarter. Stonepine Capital Management LLC now owns 590,742 shares of the biotechnology company's stock worth $3,261,000 after purchasing an additional 258,842 shares during the period. Finally, Walleye Capital LLC increased its holdings in Enanta Pharmaceuticals by 63.8% during the 1st quarter. Walleye Capital LLC now owns 27,318 shares of the biotechnology company's stock worth $151,000 after purchasing an additional 10,639 shares during the period. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Stock Performance

ENTA stock traded down $0.01 on Wednesday, hitting $9.03. 12,207 shares of the company's stock were exchanged, compared to its average volume of 269,767. Enanta Pharmaceuticals, Inc. has a 12-month low of $4.09 and a 12-month high of $13.37. The firm has a 50 day moving average price of $7.83 and a two-hundred day moving average price of $6.79. The stock has a market cap of $193.13 million, a P/E ratio of -2.10 and a beta of 0.84.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, topping the consensus estimate of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%.The firm had revenue of $18.31 million for the quarter, compared to the consensus estimate of $16.21 million. Sell-side analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on ENTA. Wall Street Zen upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday, June 22nd. HC Wainwright started coverage on Enanta Pharmaceuticals in a report on Monday, July 28th. They set a "buy" rating and a $20.00 price objective on the stock. Westpark Capital started coverage on Enanta Pharmaceuticals in a report on Tuesday, September 2nd. They issued a "buy" rating and a $24.00 price target on the stock. Finally, JMP Securities lifted their price target on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a "market outperform" rating in a report on Tuesday, August 12th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $22.25.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.